After 40 years of treating metastatic bladder cancer with chemotherapy as a primary treatment, scientists now present a new approach using immunotherapy combinations. The results of two studies have been presented at the European Society for Medical Oncology (ESMO) conference in Madrid. The outcomes of these studies could revolutionize the landscape of bladder cancer treatment.
Nivolumab and Relatlimab for Advanced Melanoma - NCI
Made-in-Canada CAR T Platform - BioCanRx
Neoadjuvant clinical trials provide a window of opportunity for cancer drug discovery
Cancer Immunotherapy Clinical Trials Continue to Grow Globally, Combination Approaches Outpace Monotherapy Trials
Tumor Microenvironment Program - USC Norris Comprehensive Cancer Center
Immunotherapy in breast cancer: an overview of current strategies and perspectives
KRAS-Targeted Therapy Doubles as Component of Immunotherapy - NCI
cellular and molecular pharmacology - presentation
An Immunotherapy Strategy Against All Blood Cancers
Immunotherapy: Pushing the Frontier of Cancer Medicine
Researchers discover why one type of chemotherapy works best in bladder cancer
Opdualag Approved to Treat Advanced Melanoma - NCI
